ARTICLE | Company News
Peregrine, AstraZeneca deal
October 5, 2015 7:00 AM UTC
The companies partnered to evaluate Peregrine’s bavituximab with AstraZeneca’s durvalumab ( MEDI4736) to treat multiple solid tumors. Peregrine will conduct a Phase I/Ib trial. Bavituximab, a chimeri...